Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib (IRESSA) plus Casodex in operable prostate cancer
2004-000495-14Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib and bicalutamide in prostate cancer (PCa), sponsored by AstraZeneca. Started Dec 2004; status: terminated.
02
Drugs
gefitinibbicalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2004-000495-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000495-14.